Indian Embassy Takes Action After ‘Doc-1 Max’ Incident with Delegation Visit
Many Children in Uzbekistan Die due to Contaminated Cough Syrup from India
In a tragic turn of events, at least 68 children in Uzbekistan have lost their lives and 16 have been left disabled due to consuming contaminated cough syrup known as “Doc-1 Max.” The medication, produced by India’s “Marion Biotech,” was found to contain toxic substances diethylene glycol (DEG) and ethylene glycol (EG) instead of or alongside propylene glycol.
Following the discovery of these harmful components, Indian authorities took swift action by arresting the director and two chemists of Marion Biotech. It was also revealed that two other directors, currently abroad, would face detention upon their return to India. Charges have been filed against the leaders of Marion Biotech and “Maya Chemtech India Pvt.” under Sections 17(a) and 17(b) of India’s Drugs and Cosmetics Act for producing and distributing substandard and dangerous drugs.
Despite these legal developments in India, there has been limited information on ongoing investigations and court proceedings. Uzbekistan’s authorities reached out to the Indian government for clarification on the matter, but as of now, there has been no response. In an effort to shed light on the situation, Kun.uz spoke with Arif Said, the Political Advisor to the Ambassador of the Indian Embassy in Uzbekistan.
Arif Said expressed concern over the lack of updates on the case and assured that the embassy was actively engaged with Uzbekistan’s government to understand the investigation findings. He emphasized India’s commitment to ensuring that its pharmaceutical products meet international standards and expressed a desire for transparency in addressing the tragedy.
The embassy has organized a delegation from India, including representatives from the Ministry of Health and Pharmaceuticals, to visit Uzbekistan and provide detailed explanations on the case. This delegation is expected to arrive in the last week of July and will address concerns and questions related to the contaminated cough syrup.
While the embassy works towards gathering comprehensive information on the matter, they have assured that once all details are confirmed, they will share them with the public. Additionally, they have not ruled out the possibility of holding a press conference to address journalist inquiries once the delegation arrives.
In response to questions about the embassy’s silence on Uzbekistan’s Ministry of Foreign Affairs inquiry, Arif Said clarified that they had sought information from India but had not received a response. The embassy continues to collaborate with relevant ministries and organizations in India to ensure accountability and transparency in this tragic incident.
As the investigation unfolds and the legal process continues, the Indian Embassy in Uzbekistan remains committed to providing updates and information to the public. The families of the affected children in Uzbekistan and the global community at large eagerly await justice and accountability for this heartbreaking tragedy.
